Navigation Links
Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
Date:10/8/2007

NEW YORK, Oct. 8 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2008 Second Quarter financial results before the U.S. stock market opens on Tuesday, October 16, 2007. Later that day, at 10:00 AM EDT, Forest will host a conference call where Dr. Lawrence Olanoff, President and Chief Operating Officer and Frank Perier, Senior Vice President and Chief Financial Officer, will discuss the financial results and relevant company and industry topics. The conference call will be webcast live beginning at 10:00 AM EDT on the Company's website http://www.frx.com and also on the website http://www.streetevents.com. Please log on to either website at least fifteen minutes prior to the conference call as it may be necessary to download software to access the call. A replay of the conference call will be available until October 31, 2007 at both websites and also by dialing 1-800-642-1687 (US investors) or +1-706-645-9291 (international investors), ID 19769552.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

About Forest Laboratories and Its Products

Forest Laboratories (http://www.frx.com) is a U.S.-based pharmaceutical company dedicated to identifying, developing, and delivering products that make a positive difference in peoples' lives. Forest Laboratories' growing product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and for generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl-D- aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate and severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.

*Benicar is a registered trademark of Daiichi Sankyo, and Campral is a registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany.

Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products and the risk factors listed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2007.


'/>"/>
SOURCE Forest Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Bird flu threat ruled out: Karnataka Forest Department
2. Will The Tropical Forests Survive The Deforestation Scenario?
3. Higher Health Cost Due to Forest Fires
4. Forest Fire Affects Singapores Air Quality
5. India to Protect Its Forests With the Aid of Austrian NGO
6. Human Induced Nitrogen Deposition Increasing Carbon Sequestration in Forests
7. Deforestation Plays a Critical Role in Climate Change: Study
8. China Unveils Green Plan to Revert Farmland to Forest
9. Northern Forests Less Effective Than Tropical Forests in Reducing Global Warming
10. International Conference On Malaria - Laveran To Genomics
11. African Conference to Combat AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2020)... (PRWEB) , ... May 23, 2020 , ... Winemaker Grant ... moment. We wanted to present something whimsical and delicious in these complicated times,” he ... Wine Blend ($34.99) and 2018 Grenache ($24.99). The Chardonnay and Red Wine Blend are ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... its first milestone to deliver over one million FDA-compliant face shields — designed, ... Face Shields meet the critical need for personal protective equipment (PPE) for both ...
(Date:5/21/2020)... (PRWEB) , ... May 21, 2020 , ... A Safe ... a donation from the $5 million AbbVie COVID-19 Community Resilience Fund. The fund was ... the needs of their frontline homeless workers in service to vulnerable populations in hard-hit ...
(Date:5/21/2020)... (PRWEB) , ... May 21, 2020 , ... ESO ... and hospitals, today announced the findings of its 2020 ESO Fire Service Index ... of EMS calls versus fire-related calls, first apparatus turnout time and travel time, the ...
(Date:5/21/2020)... ... May 21, 2020 , ... A new report from Kalorama ... 90 companies involved in the point of care test industry. Given the need ... COVID-19 has made point-of-care more important than in the past, according to the market ...
Breaking Medicine News(10 mins):
(Date:5/25/2020)... ... 25, 2020 , ... AltMed Florida , one of the fastest growing ... three-day, Memorial Day Opening, starting Monday May 25 for its newest MÜV™ Medical Cannabis ... over three-days for crowd mitigation, all licensed Florida medical cannabis patients will receive a ...
(Date:5/21/2020)... (PRWEB) , ... May 21, 2020 , ... The COVID-19 ... in March of this year, leadership at SPIRE Institute & Academy (IA) have closely ... and Ohio Governor Mike DeWine’s office to prevent the spread of coronavirus, and keep ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... 11th. The offices had been closed due to the coronavirus pandemic and the ... dental field. The office has remained open only for emergency needs and the ...
Breaking Medicine Technology: